Simultaneous determination of rofecoxib and celecoxib in human plasma by high-performance liquid chromatography

Journal of Chromatographic Science

Volumn 43, Issue 7, 2005, Pages 351-354

  Hamama, Ayman K ^a,b   Ray, John ^a   Day, Richard O ^a,c   Brien, Jo Anne E ^a,b,c  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; LACTONE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; ROFECOXIB; SULFONAMIDE; SULFONE;

ARTICLE; BLOOD; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METHODOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOOXYGENASE INHIBITORS; HUMANS; LACTONES; PYRAZOLES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SULFONAMIDES; SULFONES;

EID: 32944457915     PISSN: 00219665     EISSN: 00219665     Source Type: Journal    
DOI: 10.1093/chromsci/43.7.351     Document Type: Article

References (25)

1. J.R. Vane, Y.S. Bakhle, and R.M. Botting. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38: 97-120 (1998).
2. T. Hla and K. Neilson. Human cyclooxygenase cDNA. Proc. Natl. Acad. Sci. 89: 7384-88 (1992).
3. W.W. Seibert, Y. Zhang, K. Leahy, S. Hauser, J. Masferrer, and P. Isakson. Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv. Exp. Med. Biol. 400A: 167-70 (1997).
4. D.J. Bjorkman. The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins. Am. J. Med. 105(suppl. 1B): 8S-12S (1998).
5. B. Cryer and M. Feldman. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am. J. Med. 104(5): 413-21 (1998).
6. H. Fenner. Deferentiating among nonsteroidal antiinflammatory drugs by pharmacokinetic and pharmacodynamic profiles. Semin. Arthritis Rheum. 26(6 suppl. 1): 28-33 (1997).
7. J.R. Vane and R.M. Botting. Mechanism of action of aspirin-like drugs. Semin. Arthritis Rheum. 26(6 suppl. 1): 2-10 (1997).
8. W.W. Botten. Scientific rationale for specific inhibition of COX-2. J. Rheumatol. 51: 2-7 (1998).
9. J.B. Lefkowith. Cyclooxygenase-2 specificity and its clinical implications. Am. J. Med. 106(5B): 43S-50S (1999).
10. Vioxx (rofecoxib tablets & oral suspension package insert). Merck & Co., Inc., Whitehouse Station, NJ, 1998.
11. M.J. Rose, E.J. Woolf, and B.K. Matuszewski. Determination of celecoxib in human plasma by normal-phase high-performance liquid chromatography with column switching and ultraviolet absorbance detection. J. Chromatogr. B 738: 377-85 (2000).
12. U. Werner, D. Werner, R. Mundkowski, M. Gillich, and K. Brune. Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans. J. Chromatogr. B 760: 83-90 (2001).
13. E. Woolf, I. Fu, and B. Matuszewski. Determination of rofecoxib, a cyclooxygenase-2 specific inhibitor, in human plasma using high-performance liquid chromatography with post-column photochemical derivatization and fluorescence detection. J. Chromatogr. B 730: 221-27 (1999).
14. S. Sattari and F. Jamali. High performance liquid chromatographic determination of cyclooxygenase II inhibitor rofecoxib in rat and human plasma. J. Pharm. Pharmaceut. Sci. 3(3): 312-16 (2000).
15. M.K. Aravind, R. Prescilla, and J.P. Ofenstein. A rapid and sensitive high-performance liquid chromatographic assay for rofecoxib in human plasma. J. Chromatogr. Sci. 40: 26-28 (2002).
16. M. Zhang, G.A. Moore, S.J. Gardiner, and E.J. Begg. Determination of rofecoxib in human plasma and breast milk by high-performance liquid chromatographic assay. J. Chromatogr. B 807: 217-21 (2004).
17. M. Abdel-Hamid, L. Novotny, and H. Hamza. Liquid chromatographic-mass spectrometric determination of celecoxib in plasma using single-ion monitoring and its use in clinical pharmacokinetics. J. Chromatogr. B 753: 401-408 (2001).
18. M.S. Guirguis, S. Sattari, and F. Jamali. Pharmacokinetics of celecoxib in the presence of inteferon-induced acute inflammation in the rat: application of a novel HPLC assay. J. Pharm. Pharmaceut. Sci. 4(1): 1-6 (2001).
19. L. Tive. Celecoxib clinical profile. Rheumatology 39(suppl. 2): 21-28 (2000).
20. E. Tindall. Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results. JAOA 99(11): S13-S17 (1999).
21. L.L. Ng. Reviewer Guidance: Validation of Chromatographic Methods from the Centre for Drug Evaluation and Research (CDER). U.S. FDA, November, 1994, http://www.fda.gov/cder/guidance/cmc3.pdf.
22. V.P. Shah, K.K. Midha, J.W. Findlay, H.M. Hill, J.D. Hulse, I.J. McGilveray, G. McKay, K.J. Miller, R.N. Patnaik, M.L. Powell, A. Tonelli, C.T. Viswanatha, and A. Yacobi. Bioanalytical method validation - a revisit with a decade of progress. Pharm. Res. 17(12): 1551-57 (2000).
23. C.M. Chavez-Eng, M.L. Constanzer, and B.K. Matuszewski. Determination of rofecoxib (MK-0966), a cyclooxygenase-2 inhibitor, in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection. J. Chromatogr. B 748: 31-39 (2000).
24. C.M. Chavez-Eng, M.L. Constanzer, and B.K. Matuszewski. High-performance liquid chromatographic-tandem mass spectrometric evaluation and determination of stable isotope labeled analogs of rofecoxib in human plasma samples from oral bioavailability studies. J. Chromatogr. B 767: 117-129 (2002).
25. R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, K. Horgan, C. Lines, R. Riddell, D. Morton, A. Lanas, M.A. Konstam, and J.A. Baron. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352(11): 1092-1102 (2005).